相关实验视频
Updated: Jan 11, 2026

09:06
Intra-lymph Node Injection of Biodegradable Polymer Particles
Published on: January 2, 2014
15.1K
工程设计的非激素,阴性亲胰岛素变体延长淋巴排水
Grant M Downes1, Amber S Griffith2, Kyle D Apley3
1Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045 United States.
Molecular pharmaceutics
|November 12, 2025
概括
研究人员设计了具有阴性尾巴的亲胰岛素变体,以改善1型糖尿病的抗原特异性免疫疗法 (ASIT). 这种修改减缓了抗原的释放,增强了免疫耐受性,并可能减少了广泛免疫抑制的需要.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 生物技术是生物技术.
背景情况:
- 1型糖尿病包括针对胰腺小岛自身抗原的自身抗体,特别是亲胰岛素.
- 目前的抗原特异性免疫疗法 (ASIT) 面临着由于抗原稳定性差和快速清除的挑战.
- 现有的ASIT通常需要全球免疫抑制,带来显著的副作用.
研究的目的:
- 为增强抗原特异性免疫疗法 (ASIT) 设计稳定,非荷尔蒙性亲胰岛素变体.
- 为了研究这些修改后的亲胰岛素变体的药理动力学和药理动力学特性.
- 评估这些变异的潜力,以提高ASIT在1型糖尿病的疗效.
主要方法:
- 工程设计的非荷尔蒙性亲胰岛素变体,具有C-终端阴离子尾.
- 评估对抗胰岛素抗体和胰岛素受体的结合亲和力.
- 在氨酸凝模型中评估了物理稳定性和扩散特性.
- 模拟皮下注射以观察抗原释放动力学.
主要成果:
- 阴阳性亲胰岛素变体保持了对抗胰岛素抗体的低nM结合亲和力和低胰岛素受体亲和力.
- 这些变种的物理稳定性与原生亲胰岛素相当.
- 阴离子修饰显著减缓了亲胰岛素扩散,产生了储存效应并延长了抗原的存在.
- 缓慢释放导致持续的亲胰岛素积累在排水淋巴结.
结论:
- 亲胰岛素的阴离子修饰为开发储存式抗原递送系统提供了一个有希望的策略.
- 这种方法可以通过延长抗原暴露和向淋巴结来提高ASIT的疗效.
- 工程变体具有改善1型糖尿病治疗的潜力,通过在没有全球免疫抑制的情况下促进免疫耐受性.
相关概念视频
Insulin Formulations: Types and Delivery
632
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
632
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828

